BioNxt Solutions ( ($TSE:BNXT) ) has shared an update. BioNxt Solutions Inc. has received an ‘Intention to Grant’ notification from the European ...

Smith, a microbiologist whose discovery revolutionize the field of genetic engineering, was a Johns Hopkins School of Medicine alumnus and professor emeritus ...

US scientists have bioengineered the octopus pigment xanthommatin in bacteria, producing 1,000 times more material than ...

The Council for Scientific and Industrial Research (CSIR) has assured Ghanaians that Genetically Modified (GM) foods, particularly the Pod Borer Resistant (PBR) cowpea, were safe, nutritious, and ...

A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes towards the controversial approach.

Visit to Klang manufacturing facility held in conjunction with 14th SMIIC Technical Committee Week 2025 in Kuala Lumpur -- ...

You can review our SEC filings, the Registration Statement and Prospectus by accessing the SEC’s internet site at www.sec .g ov or on the Company’s website at www.quantumbiopharma.com, through which ...

The early-stage pipeline for amyotrophic lateral sclerosis drugs exploded last year. After ALS R&D notched 28 new trial starts in 2023, the rate more than doubled to 60 in 2024, Citeline recently ...

Tiziana Life Sciences is a buy due to its platform optionality and upcoming catalysts that outweigh its dilution risk and ...

Metis' MTS-004 was safe and eased symptoms of pseudobulbar affect in people with MS and other neurological disorders, trial data show.

Learn more about whether Biogen Inc. or Avidity Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Zenas Biopharma’s lead autoimmune drug has been tied to a 95% reduction in a type of brain lesions over 12 weeks in a phase 2 multiple sclerosis (MS) study.  | Zenas Biopharma’s lead autoimmune drug ...